# A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular Edema

> **NCT06771271** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 85 (actual)

## Conditions studied

- Diabetic Macular Edema
- Uveitic Macular Edema

## Interventions

- **DRUG:** RO7200220
- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT06771271
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-22
- **Primary completion:** 2023-11-13
- **Final completion:** 2023-11-13
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2025-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06771271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06771271, "A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular Edema". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06771271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*